Bayer tags U.S. site for sale, jeopardizing up to 300 jobs; India nixing bulk-drug price controls;

@FiercePharma: Galderma's North American president Francois Fournier gets the profile treatment from D magazine . Profile | Follow @FiercePharma

> Bayer HealthCare plans to sell a facility in Indiana, potentially putting close to 300 people out of work, local media reports. News

> India will end price controls on bulk drugs in an attempt to keep its drugmakers from abandoning API production and allowing Chinese companies to fill the gap. Story

> Pfizer ($PFE) won European approval for its drug Vyndaqel to treat a rare neurodegenerative disease, Transthyretin Familial Amyloid Polyneuropathy. Release

> Incyte's Jakafi pill won the FDA nod as a treatment for myelofibrosis, a rare bone-marrow disease, becoming the first drug approved for that condition. Article

> Chinese officials fined two pharma middlemen for cornering the market on an active ingredient, which drove up the cost of a blood-pressure medicine subject to government price controls. Story

> Hospira ($HSP) launched a generic version of Merck's ($MRK) antibiotic drug Primaxin in the U.S. Report

> Cadence Pharmaceuticals raised about $67 million in a stock offering to finance marketing of its fever and pain treatment Ofirmev. News

> The Generic Pharmaceutical Association spent $548,315 lobbying Washington in the third quarter on issues such as budget cuts and healthcare reform. Story

> U.S.-based Polaris plans to plough $50 million into a new cancer-drug production facility in Taiwan. Article

> PharMerica's poison pill may yield the biggest price increase in takeover history as Omnicare continues to pursue a buyout. News

> South African health activists are trying to persuade the government to use WTO powers to promote generic versions of on-patent meds. Report

Biotech News

@FierceBiotech: Pfizer won expert backing for Prevnar 13 in adults for pneumonia, meningitis and other pneumococcus bacteria diseases. Item | Follow @FierceBiotech

@JohnCFierce: EC aims at boosting antibiotic R&D with a public/private initiative, via Reuters . Report | Follow @JohnCFierce

@RyanMFierce: Agios attracts 3 large public investors, Celgene and VCs in $78M C round. Story | Follow @RyanMFierce

> Agios adds $78M C round to back cancer drug portfolio. Item

Vaccines News

> FDA experts back Pfizer's Prevnar 13 for older adults. Article

> GAVI to bring HPV vaccines to poor countries. Story

> Experts: Video on Delta flights misleading about vaccines. News

> Weakness found in deadly malaria parasite. Report

Manufacturing News

> Aesica CEO Hardy makes CDMO business fly. News

> Novartis workers strike to forestall plant closure. Item

> Merck leans on suppliers, partners to expand reach. Article

> Strikers want Dr. Reddy promise of regular work. Story

> UCB to set up major bioprocessing plant in Switzerland. Report

And Finally... Drug resistance is growing in Europe, with rates in some bacteria approaching 50%, European public health officials said. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.